Progression to HCC in HCV-infected patients in the REVEAL II cohort, Taiwan in relation to IFNL4 genotype and SVR after treatment/retreatment with peg-IFNα/RBV. The gene discussed is IFNL4; the disease is hepatocellular carcinoma.